Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 23, 2025 08:45 ET | Source: Amplia Therapuetics Limited

Amplia Therapeutics to Present at 2026 ASCO Gastrointestinal Cancers Symposium

Melbourne, Australia, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF) (“Amplia” or the “Company”) is pleased to announce that the Company’s CMO Dr Jason...
December 19, 2025 08:45 ET | Source: Amplia Therapuetics Limited

Amplia Enters into Second Agreement with Korean Specialist Drug Screening Company Next&Bio to Explore Combination Therapy with FAK Inhibitor and kRAS Inhibitors

HIGHLIGHTS The preclinical research collaboration with specialist drug screening company Next & Bio has been extendedThe collaboration explores the effect of Amplia’s FAK inhibitors in...
December 12, 2025 08:45 ET | Source: Amplia Therapuetics Limited

Additional Confirmed Response Reported as Part of Amplia Investor Presentation

HIGHLIGHTS An additional confirmed partial response has been recorded in the ongoing ACCENT trialThis brings the confirmed Objective Response Rate to 35%Updated data to be presented at the Life...
December 03, 2025 08:45 ET | Source: Amplia Therapuetics Limited

Key Narmafotinib Patent Granted in the U.S.

Highlights The Company has received a Certificate of Grant from the US Patent and Trademark Office for a key patent for the FAK inhibitor narmafotinibThe patent extends protection for narmafotinib to...